Presage Announces FDA Study May Proceed to Evaluate Candidate in CIVO Ph 0 Trial
SEATTLE, Nov. 28, 2022 /PRNewswire/ -- Presage Biosciences a biotechnology company whose mission is understanding the complexity of drug response in the tumor microenvironment, today announced completion of a first-of-its-kind Phase 0 clinical study utilizing its CIVO® (Comparative In Vivo Oncology) multiplexed microdosing technology. Presage evaluated an investigational immuno-oncology agent, subasumstat, alone and in combination with other immuno-oncology agents. The spatial biology and mechanistic insights generated from this fully-enrolled Phase 0 study not only provided additional target validation in patient tumors, but also delivered unique drug combination and pharmacodynamic biomarker data with the potential to inform further clinical development of the investigational therapy.